anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:The bile acid salt of the compound of formula I (R<1> is H or lower alkyl; R<2> and R<3> are H or CH3; X is alkylene derived from 1-7C alkyl; BA is bile acid). EXAMPLE:dl-alpha-tocopherol aminoacetic acid ester taurocholic acid salt. USE:A drug. It is white powder easily soluble in water to enable the preparation of a solution having a concentration of >=100mM. It is useful as an aqueous injection or instillation having extremely low hemolytic activity and applicable by intravenous injection. Since the compound is obtained in powdery form, it can be easily and simply handled in drug preparation. It is added with a pH modifier, a buffering agent, etc., and parenterally administered once or several times a day. PREPARATION:Bile acid salt of the compound of formula I can be produced e.g. by reacting a tocopherol aminoalkylcarboxylic acid ester of formula II with bile acid of formula BA in a solvent such as methanol and distilling the solvent under reduced pressure.
465,881. Hair - curling. DOBSON, R. T. Nov. 15, 1935, No. 31673. [Class 131] A sachet, pad, or wrapper for use in waving or curling hair has formed integral with or attached to it an indicator treated with a chemical which, when the hair has been wetted and subjected to heat,-will be acted upon by the vapours evolved to give an indication of the progress of the treatment. It is explained in the Specification that hair of fine texture requires a more prolonged or more vigorous treatment than hair of coarse texture and three examples of solutions suitable for coarse, medium and fine hair are given: (1) À880 ammonia 2“ fluid ozs., sodium sulphite “ oz. ; (2) À880 ammonia 3 fluid ozs., sodium sulphite ¢ oz.; and (3) À880 ammonia 4 fluid ozs., sodium sulphite ¥ oz., triethanolamine salt of lauryl alcohol in liquid form “ dram, with water to 20 ozs. in each case. 1 Per cent. of a non-volatile acid such as citric acid may be added to reduce the pH value of the solution. With these solutions, a suitable chemical for the indicator would be 1-6 per cent phenol phthalein in alcohol. The indicator may comprise a paper backing for the sachet or a separate strip attached to the heater or paper wrapping and impregnated with the phenol phthalein. The indicator changes colour as the vapours are evolved and returns to its normal colour when the alkaline vapours have been disposed. To ensure a return to normal colour, the indicator may be impregnated with an acid which also serves to neutralize any small quantity of alkaline solution which might be splashed on it. According to the Provisional Specification, a solution for use with all kinds of hair may contain several constituents which boil at different temperatures, the vapours being of different acidity or alkalinity. The indicator in this case may contain a number of different constituents which respond to different degress of acidity or alkalinity.
Patients will receive the nutritional supplement for 5 days prior to surgery and for 5 days after. The drink will contain arginine.
The aim of this study is to investigate the effect of proprioceptive neuromuscular facilitation (PNF) and static stretching techniques on the balance and functional capabilities of children diagnosed with diplegic cerebral palsy (CP). The study consisted of a group of sixteen children, ranging in age from 8 to 16 years, who were diagnosed with bilateral hip flexor contracture and diplegic cerebral palsy. These children were classified according to the Gross Motor Function Classification System (GMFCS) levels I to III. The children were randomly divided into PNF and static stretching groups. Stretching techniques were applied 2 days a week for 4 weeks, with 6 repetitions in each session. The study assessed various parameters, including hip extension range of motion (ROM), muscle tone intensity based on the Modified Ashworth Scale, hip flexor shortness as determined by the Thomas Test, the time up and go (TUG) test, balance using the Pediatric Berg Balance Scale, and functional status evaluated through the Gilette Functional Walking Assessment Questionnaire.
PROBLEM TO BE SOLVED: To provide both a raw material for a hair tonic and a hair tonic composition, having an excellent hair restoring effect and high safety without imparting objectionable stimulation to scalp. SOLUTION: This raw material for a hair tonic is characterized by comprising an extract prepared from Rinacanthus nasutusu. This hair tonic composition is characterized by including the raw material for a hair tonic and is e.g. cosmetics, medicaments or unregulated drugs. Rinacanthus nasutusu is a kind of medicinal herbs belonging to the genus Rinacanthus Nees in the Acantheceae family and is a herb having 50-150 cm height. It is farmed mainly in tropical Africa, India, Thai and Malaysia, and can also be seen in a wild state.
Adolescents with CP classified as Gross Motor Functional Classification System Level V attend school up to 8 h daily with limited ability to self-reposition. Despite pain reported within this population, perceived pain and self-pressure relief during prolonged classroom sitting is unknown. A case series design was used with a convenience sample of six students (13-18 years) with CP. Pain assessments were taken every 30 min for 5 h. Self-relief assessments using the SensiMATTM were recorded while students were in their wheelchairs. One student self-reported pain and three students proxy reported pain movements. All students had unrelieved pressure or did not self-relieve pressure for at least 1.5 consecutive hours. Four students increased their self-pressure relief movements after 3.5 h. This study provided preliminary data regarding perceived pain and self-pressure relief during prolonged sitting and demonstrated that the SensiMATTM can capture pressure relief movements in sitting of students with severe CP. Although there was no trend of reported pain, students may either be moving enough, as demonstrated by recorded pressure relief movements, to independently relieve pressure and pain, or current pain assessments may not be sensitive enough for those with the most severe disabilities.
PURPOSE:To obtain a compound having thromboxane A2 antagonistic action and useful as a platelet aggregation suppressing agent by reducing an indane derivative and condensing with a sulfonic acid. CONSTITUTION:The objective compound of formula II can be produced by reducing a compound of formula I (R<1> is -SO3R or H; R is phenyl, naphthyl or sulfur-containing heterocyclic group; R<2> is H or lower alkyl; R<3> is lower alkoxycarbonyl-lower alkyl, etc.; Y is phenylmercaptomethylene, lower alkylmercaptomethylene, carbonyl, etc.) or its salt to convert the group Y into methylene group and, when R<1> is H, condensing the reduction product with a sulfonic acid compound of formula RSO3H or its reactive derivative. The starting compound of formula I is novel compound which can be produced by condensing a compound of formula III (R<11> is -SO2R or amino-protecting group) with a compound of formula IV (Y<1> is phenylmercaptomethylene, etc.; X is halogen).
The new ideal is the transfusion of natural blood, artificial blood plasma or artificial blood plasma mixed with natural blood, while draining natural blood for therapy of poison, snake bite, leukemia, aged persons, other cancers, allergies and other undiscovered uses. Some concerns in such blood therapy, is the blood be live, well warmed and well oxygenated, possibly with a heart lung machine. Also, that blood pressure is carefully monitored. If artificial blood plasma is substituted for whole blood, the concern would be careful monitoring for internal and external bleeding as artificial blood plasma does not clot. These therapies are not warranted to improve health. These are untested medical therapies and the inventor and Therapy Patent Corporation accepts no risk or liability for loss of health or death that may occur do to experimental work that may occur with these therapies. Perhaps testing and experimentation on animals should be considered before testing and experimentation on humans is considered.
Optimal Nutrition of the critically ill is still a clinical challenge. Current guidelines recommend that measurement of energy expenditure using indirect calorimetry should be favoured in critically ill patients. The technique is based on measurement of oxygen consumption and carbon dioxide elimination. Experimental studies have reported on carbon dioxide elimination via renal replacement therapy. Since acute kidney injury with requirement for renal replacement therapy (RRT) is common in the intensive care unit, the significance of carbon dioxide elimination via the dialyser should be clarified. However, available evidence from clinical studies is contradictory, one reason being the heterogenous study design.

In this prospective observational study on critically ill mechanically ventilated medical patients requiring RRT, indirect calorimetry (IC) will be conducted twice on the same day with and without RRT: either immediately before commencement of RRT followed by a second IC with RRT after an RRT run time of an hour, or immediately before the end of an RRT session followed by a second IC an hour after the termination of RRT.
Patients belonging to group A will start intervention I, immediately after baseline. We will recruit about 25 for group A (randomization will take into account the two to one study design) in order to have about 20 patients in Group A that will complete the study.
Acute thymic atrophy occurs following type 1 inflammatory conditions such as viral infection and sepsis, resulting in cell death and disruption of T cell development. However, the impact type 1 immunity has on thymic-resident innate lymphoid cells (ILCs) remains unclear. Single-cell RNA sequencing revealed neonatal thymic-resident type 1 ILCs (ILC1s) as a unique and immature subset compared to ILC1s in other primary lymphoid organs. Culturing murine neonatal thymic lobes with the type 1 cytokines interleukin-12 (IL-12) and IL-18 resulted in a rapid expansion and thymic egress of KLRG1+CXCR6+ cytotoxic ILC1s. Live imaging showed the subcapsular thymic localization and exit of ILC1s following IL-12 + IL-18 stimulation. Similarly, murine cytomegalovirus infection in neonates resulted in thymic atrophy and subcapsular localization of thymic-resident ILC1s. Neonatal thymic grafting revealed that type 1 inflammation enhances the homing of cytokine-producing thymus-derived ILC1s to the liver and peritoneal cavity. Together, we show that type 1 immunity promotes the expansion and peripheral homing of thymic-derived ILC1s.
Anorexia nervosa (AN) is a serious and often chronic eating disorder characterized by restrictive eating habits and failure to maintain a healthy minimal body weight. Symptoms of AN may include distorted body image, fear of weight gain, obsessive exercise, and binge and purge eating behaviors. In severe cases of AN, a person may practice extreme dieting to levels of near starvation. These unhealthy behaviors may cause further medical complications, including organ damage, irregular heart rhythm, premature osteoporosis, and heart failure. AN has one of the highest mortality rates of all psychiatric disorders, claiming the lives of up to 6% of those affected. When treated with a form of psychotherapy and nutritional guidance, people can restore weight to healthy levels and recover from AN, but the chance of relapse remains high. A program aimed specifically at reducing relapse, Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP), may be more effective than common psychotherapy treatments, such as cognitive behavioral therapy (CBT), in enhancing long-term recovery from AN. This study will compare the effectiveness of AN-EX/RP with CBT in reducing relapse and fear of eating situations in people with AN.

Participants in this study will include patients who have achieved normal weight while inpatients at the New York State Psychiatric Unit. Eligible participants will undergo initial assessments that will include questionnaires, interviews, and two laboratory-based meals. Participants will then be assigned randomly to receive 6 months of outpatient psychotherapy treatment with either AN-EX/RP or CBT. Participants assigned to receive AN-EX/RP will attend 90-minute sessions twice weekly for the first few months, then weekly thereafter. Sessions will focus on fear of eating situations and will help participants to confront, rather than avoid, these fears in order to learn through practice that the fears are unrealistic. Participants assigned to receive CBT will attend treatment sessions twice weekly for the first month and then weekly thereafter. CBT sessions will focus on thoughts, feelings, and behaviors that perpetuate the eating disorder, with the aim to develop healthier patterns. After completing the 6 months of treatment, all participants will repeat the initial assessments.
* Testosterone topical solution is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate [see WARNINGS AND PRECAUTION (5.1)] .
  * Testosterone topical solution is contraindicated in women who are, or who may become pregnant, or who are breastfeeding. Testosterone topical solution may cause fetal harm when administered to a pregnant woman. Testosterone topical solution may cause serious adverse reactions in nursing infants. If a pregnant woman is exposed to testosterone topical solution, she should be apprised of the potential hazard to the fetus. [see USE IN SPECIFIC POPULATIONS (8.1,8.3)] .
The efficacy of clobetasol propionate lotion, 0.05% in psoriasis and atopic dermatitis has been demonstrated in two adequate and well-controlled clinical trials. The first trial was conducted in subjects with moderate to severe plaque psoriasis. Subjects were treated twice daily for 4 weeks with either clobetasol propionate lotion, 0.05% or vehicle lotion. Trial results demonstrated that the efficacy of clobetasol propionate lotion, 0.05% in treating moderate to severe plaque psoriasis was superior to that of vehicle.

At the end of treatment (4 weeks), 30 of 82 subjects (36.6%) treated with clobetasol propionate lotion, 0.05% compared with 0 of 29 (0%) treated with vehicle achieved success. Success was defined as a score of none or very mild (no or very slight clinical signs or symptoms of erythema, plaque elevation, or scaling) on the Global Severity scale of psoriasis.

The second trial was conducted in subjects with moderate to severe atopic dermatitis. Subjects were treated twice daily for 2 weeks with either clobetasol propionate lotion, 0.05% or vehicle lotion. Trial results demonstrated that the efficacy of clobetasol propionate lotion, 0.05% in treating moderate to severe atopic dermatitis was superior to that of vehicle. At the end of treatment (2 weeks), 41 of 96 subjects (42.7%) treated with clobetasol propionate lotion, 0.05% compared with 4 of 33 (12.1%) treated with vehicle achieved success. Success was defined as a score of none or very mild (no or very slight clinical signs or symptoms of erythema, induration/papulation, oozing/crusting, or pruritus) on the Global Severity scale of atopic dermatitis.
Besides sepsis and malignancy, malperfusion is the third leading cause of tissue degradation and a major pathomechanism for various medical and surgical conditions. Despite significant developments such as bypass surgery, endovascular procedures, extracorporeal membrane oxygenation, and artificial blood substitutes, tissue malperfusion, especially of visceral organs, remains a pressing issue in patient care. The demand for further research on biomedical processes and possible interventions is high. Valid biological models are of utmost importance in enabling this kind of research. Due to the multifactorial aspects of tissue perfusion research, which include not only cell biology but also vascular microanatomy and rheology, an appropriate model requires a degree of biological complexity that only an animal model can provide, rendering rodents the obvious model of choice. Tissue malperfusion can be differentiated into three distinct conditions: (1) isolated arterial ischemia, (2) isolated venous congestion, and (3) combined malperfusion. This article presents a detailed step-by-step protocol for the controlled and reversible induction of these three types of visceral malperfusion via midline laparotomy and clamping of the abdominal aorta and caval vein in rats, underscoring the significance of precise surgical methodology to guarantee uniform and dependable results. Prime examples of possible applications of this model include the development and validation of innovative intraoperative imaging modalities, such as Hyperspectral Imaging (HSI), to objectively visualize and differentiate malperfusion of gastrointestinal, gynecological, and urological organs.
BACKGROUND: Gastric electrical stimulation (GES) is an intervention used in the treatment of medically refractory gastroparesis. There are few large series demonstrating efficacy over a long-term follow-up period. This study reports clinical outcomes for patients from a single institution for up to 5 years.
STUDY DESIGN: A prospective database of patients undergoing GES implantation for gastroparesis was collected and reviewed. Patients were selected according to a multidisciplinary institutional protocol. Baseline characteristics, including age, sex, smoking history, etiology of gastroparesis, and duration of gastroparesis symptoms, were collected. Symptomatic response was evaluated using Gastroparesis Cardinal Symptom Index (GCSI) surveys preoperatively and at subsequent follow-up visits. Other clinical outcome variables include medication use, hospitalizations due to gastroparesis, and overall satisfaction with symptom relief. Patient outcomes regarding reoperation and explantation were also recorded.
RESULTS: A total of 157 patients have undergone GES at our institution since 2012. GCSI scores were collected in all patients at baseline, in 141 patients at 1-year follow-up, and in 110 patients at 5-year follow-up. Symptom severity in all 9 gastroparesis symptoms evaluated by the GCSI, as well as the total GCSI score, was reduced significantly at 1 year postoperatively, and these results were sustained at 5-year follow-up. Use of prokinetic and antiemetic medications was reduced during the follow-up period. Hospitalizations due to gastroparesis symptoms were also reduced. GES devices were explanted in 5 patients, 12 patients required generator exchanges, and 7 patients required reoperation due to displaced or eroded device leads during the study period.
CONCLUSIONS: GES is associated with sustained symptomatic relief, reduced reliance on medications, and reduced hospitalizations in gastroparesis patients selected using our institutional protocol.
Atherosclerosis (AS) is the root cause of cardiovascular diseases. Ferroptosis is characterized by highly iron-dependent lipid peroxidation and has been reported to play an important role in the pathogenesis of AS. Visualization of the ferroptosis process in atherosclerotic plaques is of great importance for diagnosing and treating AS. In this work, the rationally designed fluorescent probe FAS1 exhibited excellent advantages including large Stokes shift, sensitivity to environmental viscosity, good photostability, and improved water solubility. It also could co-locate with commercial lipid droplets (LDs) probes (BODIPY 493/503) well in RAW264.7 cells treated by the ferroptosis inducer. After self-assembly into nanoparticles and then encapsulation with macrophage membranes, the engineered FAS1@MM NPs could successfully target the atherosclerotic plaques in Western diet-induced apolipoprotein E knockout (ApoE-/-) mice and reveal the association of ferroptosis with AS through fluorescence imaging in vivo. This study may provide additional insights into the roles of ferroptosis in the diagnosis and treatment of AS.
Steroid hormones are solubilized by a pyridine derivative of formula <FORM:0761618/VI/1> where R is an alkoxy, amino or substituted amino radical. Specified derivatives include methyl nicotinate, ethyl nicotinate, methyl isonicotinate, nicotinamide, N, N-diethyl nicotinamide, isonicotnic acid hydrazide and pyrizinamide. Adrenal hormones (cortisone, hydrocortisone, corticosterone, desoxycorticosterone and dehydrocorticosterone), estrogenic hormones (a -estradiol), corpus luteum hormone (progesterone) and androgenic hormones (testosterone), alone or mixed, may be solubilized.  The composition gives a solution on addition of water or a medicinally acceptable oil.  Benzyl alcohol may also be present.  The solutions formed may be used for oral, topical, intramuscular, intravenous, opthalmic, nasal or irrigational administration.  An example describes the preparation of an aqueous solution of hydrocortisone alcohol and nicotinamide.
Severe hypertension occurred at a higher incidence in patients receiving bevacizumab products as compared to patients receiving chemotherapy alone. Across clinical studies, the incidence of Grades 3–4 hypertension ranged from 5% to 18%.

Monitor blood pressure every two to three weeks during treatment with ZIRABEV. Treat with appropriate anti-hypertensive therapy and monitor blood pressure regularly. Continue to monitor blood pressure at regular intervals in patients with ZIRABEV-induced or -exacerbated hypertension after discontinuing ZIRABEV. Withhold ZIRABEV in patients with severe hypertension that is not controlled with medical management; resume once controlled with medical management. Discontinue in patients who develop hypertensive crisis or hypertensive encephalopathy.
BACKGROUND: Segmenting colorectal polyps presents a significant challenge due to the diverse variations in their size, shape, texture, and intricate backgrounds. Particularly demanding are the so-called "camouflaged" polyps, which are partially concealed by surrounding tissues or fluids, adding complexity to their detection.
METHODS: We present CPSNet, an innovative model designed for camouflaged polyp segmentation. CPSNet incorporates three key modules: the Deep Multi-Scale-Feature Fusion Module, the Camouflaged Object Detection Module, and the Multi-Scale Feature Enhancement Module. These modules work collaboratively to improve the segmentation process, enhancing both robustness and accuracy.
RESULTS: Our experiments confirm the effectiveness of CPSNet. When compared to state-of-the-art methods in colon polyp segmentation, CPSNet consistently outperforms the competition. Particularly noteworthy is its performance on the ETIS-LaribPolypDB dataset, where CPSNet achieved a remarkable 2.3% increase in the Dice coefficient compared to the Polyp-PVT model.
CONCLUSION: In summary, CPSNet marks a significant advancement in the field of colorectal polyp segmentation. Its innovative approach, encompassing multi-scale feature fusion, camouflaged object detection, and feature enhancement, holds considerable promise for clinical applications.
After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.